1. Home
  2. NREF vs DRUG Comparison

NREF vs DRUG Comparison

Compare NREF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NREF
  • DRUG
  • Stock Information
  • Founded
  • NREF 2019
  • DRUG 2019
  • Country
  • NREF United States
  • DRUG United States
  • Employees
  • NREF N/A
  • DRUG N/A
  • Industry
  • NREF Real Estate Investment Trusts
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • NREF Real Estate
  • DRUG Health Care
  • Exchange
  • NREF Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • NREF 275.2M
  • DRUG 260.6M
  • IPO Year
  • NREF 2020
  • DRUG N/A
  • Fundamental
  • Price
  • NREF $15.63
  • DRUG $35.99
  • Analyst Decision
  • NREF Hold
  • DRUG Strong Buy
  • Analyst Count
  • NREF 4
  • DRUG 4
  • Target Price
  • NREF $14.75
  • DRUG $84.33
  • AVG Volume (30 Days)
  • NREF 27.3K
  • DRUG 69.2K
  • Earning Date
  • NREF 02-27-2025
  • DRUG 03-04-2025
  • Dividend Yield
  • NREF 12.86%
  • DRUG N/A
  • EPS Growth
  • NREF N/A
  • DRUG N/A
  • EPS
  • NREF 1.32
  • DRUG N/A
  • Revenue
  • NREF $73,164,000.00
  • DRUG N/A
  • Revenue This Year
  • NREF N/A
  • DRUG N/A
  • Revenue Next Year
  • NREF $34.61
  • DRUG N/A
  • P/E Ratio
  • NREF $11.75
  • DRUG N/A
  • Revenue Growth
  • NREF 224.04
  • DRUG N/A
  • 52 Week Low
  • NREF $12.63
  • DRUG $0.93
  • 52 Week High
  • NREF $18.09
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • NREF 51.15
  • DRUG 43.58
  • Support Level
  • NREF $15.35
  • DRUG $40.10
  • Resistance Level
  • NREF $15.84
  • DRUG $47.50
  • Average True Range (ATR)
  • NREF 0.36
  • DRUG 3.56
  • MACD
  • NREF 0.03
  • DRUG -0.51
  • Stochastic Oscillator
  • NREF 73.08
  • DRUG 23.22

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. It provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: